Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromesMaría‐Teresa Cedena, Joaquín Martínez‐López, Inmaculada Rapado et al.|Oncotarget|2017Cited by 43
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trialCatia Simoes, Pau Montesinos, Lorenzo Algarra et al.|Blood Advances|2021Cited by 25
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical TrialRosa Ayala, Inmaculada Rapado, Esther Onecha et al.|Cancers|2021Cited by 12
Mutations in DNA Methylation Pathway and Number of Driver Mutations Predict Response to Azacitidine in Myelodysplastic SyndromesMaría‐Teresa Cedena, Joaquín Martínez‐López, Inmaculada Rapado et al.|Leukemia Research|2017Cited by 6
S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIBJuan Miguel Bergua Burgués, Pau Montesinos, Rebeca Rodríguez‐Veiga et al.|HemaSphere|2023Cited by 6